- Future Students
- DVM degree program
- Graduate Programs
- Request information
- Contacts, Map, and Directions
- Current Students
- Faculty & Staff
Functional interleukin-2 receptors are expressed on natural killer-like leukemic cells from a dog with cutaneous lymphoma.
|Title||Functional interleukin-2 receptors are expressed on natural killer-like leukemic cells from a dog with cutaneous lymphoma.|
|Publication Type||Journal Article|
|Year of Publication||1995|
|Authors||Helfand SC, Modiano JF, Moore PF, Soergel SA, MacWilliams PS, Dubielzig RD, Hank JA, Gelfand EW, Sondel PM|
|Date Published||1995 Jul 15|
|Keywords||Animals, Cytotoxicity, Immunologic, Dog Diseases, Dogs, Female, Humans, Immunophenotyping, Interleukin-2, Killer Cells, Natural, Lymphoma, Large B-Cell, Diffuse, Lymphoproliferative Disorders, Neoplasm Proteins, Neoplastic Stem Cells, Receptors, Interleukin-2, Recombinant Proteins, Skin Neoplasms|
We identified a dog with large granular lymphocytic leukemia and cutaneous lymphoma that exhibited constitutive expression of interleukin-2 (IL-2) receptors by the leukemic peripheral blood lymphocytes. The leukemic cells phenotypically resembled natural killer (NK) cells, and their surface IL-2 receptors were functional, as determined by the capacity to bind human recombinant IL-2 with high-affinity resulting in the transduction of proliferation signals and in the development of lymphokine-activated killer cell activity. These cells produced IL-2 spontaneously, and they may have maintained their proliferative state through an IL-2-dependent autocrine growth pathway. Our results indicate that neoplastic lymphocytes of syndromes that involve circulating leukemic cells with dermotropism can originate from NK-like cells. Additionally, the data also suggest that proliferative conditions such as these may be the result of the aberrant production of IL-2. Further, this case illustrates the potential for the use of hematopoietic malignancies in the dog as a suitable animal model for immune targeting of IL-2 receptors as a novel treatment approach for similar malignancies of human beings.